Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy

• Status: Active, not recruiting
• Trial end date: 2020-12-31
• Target enrollment: 40
• Participant gender: All

Summary

The study proceeds with prospective, randomized, open and controlled clinical trials. The subject of the investigator's study was the first patient diagnosed with dilated cardiomyopathy. Subjects who agreed to participate in the study and were determined to meet the selection / exclusion criteria were randomly assigned to each group, and the experimental group was treated with 20 mg of olmesartan and 5 mg of rosuvastatin for 6 months, and the control group is treated with 40 mg of valsartan and 5 mg of rosuvastatin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A University
• Treatments: Olmesartan; Olmesartan Medoxomil; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• dilated cardiomyopathy

Exclusion Criteria:

• contraindication to angiotensin receptor blocker

• cardiogenic shock

• sensitive to rosuvastatin

• liver cirrhosis more than Child class B